Pacific Biosciences of California Stock News

Cathie Wood stocks have been on a big roll lately, as Ark Innovation ETF (NYSEARCA: ARKK ) soared 31% in November, with Coinbase (NASDAQ: COIN ), Roku (NASDAQ: ROKU ), Shopify (NYSE: SHOP ) and CRISPR

Pacific Biosciences reported a 72% YoY revenue growth in Q3 2023, driven by the successful launch of their Revio platform. The adoption of Revio by new customers and the potential to convert existing

PacBio (PACB) witnesses strong revenue growth in the third quarter, partly aided by customers' continued product transition to the Revio system.

Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q3 2023 Earnings Conference Call October 30, 2023 4:30 PM ET Company Participants Todd Friedman - Senior Director, Investor Relations Christian H

PacBio's (PACB) product development activities raise optimism about the stock.

Pacific Biosciences (PACB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price in

Pacific Biosciences has a leading position within the fast-growing long-read DNA sequencer market. Moreover, it is expanding its high-accuracy long-read portfolio to grab more market share from Illumi

Cathie Wood recently bought shares of Beam Therapeutics, a clinical-stage drugmaker testing out a new way to edit troublesome genes. Ark Invest also acquired shares of Pacific Biosciences of Californi

PacBio's (PACB) product development activities raise optimism about the stock.

Cathie Wood bought shares of Palantir, PacBio, and Global-e Online on Tuesday. Palantir posted its weakest quarterly revenue growth as a public company, but it still exceeded its earlier guidance.

PacBio (PACB) and GeneDx sign a deal with the University of Washington to study long-read sequencing in rare diseases. The study will use PacBio's Revio system to explore novel variants.

PacBio (PACB) witnesses strong revenue growth in the second quarter, partly aided by customers' product transition to the Revio system.

Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.34 per share a year ago.

Pacific Biosciences (PACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PacBio (PACB) receives new order for its Revio system from Bioscientia that will boost the latter's services. Here's how Revio can help Bioscientia improve diagnosis and treatment for monogenic disord